Acepodia (ROCO:6976) EBIT per Share : NT$-54.91 (TTM As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Acepodia EBIT per Share?

Acepodia's EBIT per Share for the six months ended in Jun. 2023 was NT$-54.57. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-54.91.

During the past 3 years, the average EBIT per Share Growth Rate was 61.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Acepodia's EBIT per Share or its related term are showing as below:

ROCO:6976' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 61.3 Med: 61.3 Max: 61.3
Current: 61.3

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Acepodia was 61.30% per year. The lowest was 61.30% per year. And the median was 61.30% per year.

ROCO:6976's 3-Year EBIT Growth Rate is ranked better than
96.08% of 1300 companies
in the Biotechnology industry
Industry Median: 3.4 vs ROCO:6976: 61.30

Acepodia's EBIT for the six months ended in Jun. 2023 was NT$-617.14 Mil.

Acepodia EBIT per Share Historical Data

The historical data trend for Acepodia's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acepodia EBIT per Share Chart

Acepodia Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-40.23

-77.62

-30.76

-1.43

Acepodia Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial			-	357.10	-131.91	-54.57	-0.34

Acepodia EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Acepodia's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-811.699	/	567.016
=	-1.43

Acepodia's EBIT per Share for the quarter that ended in Jun. 2023 is calculated as

	EBIT per Share		(Q: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-617.135	/	11.309
=	-54.57

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-54.91

Acepodia (ROCO:6976) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Acepodia EBIT per Share Related Terms

Thank you for viewing the detailed overview of Acepodia's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Acepodia (ROCO:6976) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acepodia Inc (ROCO:6976) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

17th floor-12, Number 99, Section 1, Xintai 5th Road, Xizhi District, New Taipei, TWN, 22175

Website

https://www.acepodia.com

Acepodia Inc is a clinical stage biotechnology company engaged to develop innovative highly effective first-in-class cell therapies by using Antibody-Cell Conjugation platform technology for cancer that are broadly accessible for patients.

Acepodia (ROCO:6976) Headlines

No Headlines